
Cidara Therapeutics Inc CDTX.OQ CDTX.O is expected to show a fall in quarterly revenue when it reports results on May 8 for the period ending March 31 2025
LSEG's mean analyst estimate for Cidara Therapeutics Inc is for a loss of $3.54 per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Cidara Therapeutics Inc is $35.00, above its last closing price of $21.50.
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Dec. 31 2024 | -3.52 | -3.62 | -5.37 | Missed | -48.3 |
Sep. 30 2024 | -3.55 | -4.25 | -2.45 | Beat | 42.4 |
Jun. 30 2024 | -4.01 | -3.22 | -1.39 | Beat | 56.9 |
Mar. 31 2024 | -0.20 | -0.20 | -2.28 | Missed | -1,040 |
Dec. 31 2023 | -2.07 | -0.80 | Beat | 61.3 | |
Sep. 30 2023 | -3.19 | -3.25 | -1.80 | Beat | 44.6 |
Jun. 30 2023 | -2.04 | -2.60 | -2.80 | Missed | -7.7 |
Mar. 31 2023 | -0.41 | -0.73 | 0.60 | Beat | 181.8 |
This summary was machine generated May 6 at 20:15 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)